Search

Your search keyword '"Gerretsen, J.J.F."' showing total 15 results
Start Over Author "Gerretsen, J.J.F."
15 results on '"Gerretsen, J.J.F."'

2. Molecular mechanisms and treatment responses of pulmonary fibrosis in severe COVID-19

Author

Kooistra, E.J., Dahm, Kilian, Herwaarden, A.E. van, Gerretsen, J.J.F., Germano, Melanie Nuesch, Mauer, Karoline, Smeets, R.L., Velde, Sjef van der, Berg, M.J.W. van den, Hoeven, J.G. van der, Kox, M., Pickkers, P., Kooistra, E.J., Dahm, Kilian, Herwaarden, A.E. van, Gerretsen, J.J.F., Germano, Melanie Nuesch, Mauer, Karoline, Smeets, R.L., Velde, Sjef van der, Berg, M.J.W. van den, Hoeven, J.G. van der, Kox, M., and Pickkers, P.

Abstract

Item does not contain fulltext

Published
2023

3. The gut microbiota composition has no predictive value for the endotoxin-induced immune response or development of endotoxin tolerance in humans in vivo

Author

Bruse, N., Jansen, A., Gerretsen, J.J.F., Rijbroek, Danielle, Wienholts, K., Arron, M.N.N.J., Ederveen, T.H., Pickkers, P., Kox, M., Bruse, N., Jansen, A., Gerretsen, J.J.F., Rijbroek, Danielle, Wienholts, K., Arron, M.N.N.J., Ederveen, T.H., Pickkers, P., and Kox, M.

Abstract

Contains fulltext : 297912.pdf (Publisher’s version ) (Open Access)

Published
2023

5. A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients

Author

Kooistra, E.J., Nooijer, A.H. de, Claassen, W.J., Grondman, I., Janssen, N.A.F., Netea, M.G., Veerdonk, F.L. van de, Hoeven, J.G. van der, Hemelaar, P., Beunders, R., Frenzel, T., Schouten, J.A., Gerretsen, J.J.F., Heesakkers, H.G.P., Joosten, L.A.B., Mast, Q. de, Jaeger, M., Kouijzer, I.J.E., Dijkstra, H.I., Lemmers, H.L.M., Crevel, R. van, Maat, J.S. van de, Moorlag, S.J.C.F.M., Taks, E.J.M., Debisarun, A., Wertheim, H.F.L., Hopman, J., Rahamat-Langendoen, J.C., Bleeker-Rovers, C.P., Koenen, H.J., Fasse, E., Rijssen, E. van, Cranenbroek, B. van, Smeets, R.L., Joosten, I., Kox, M., Pickkers, P., Kooistra, E.J., Nooijer, A.H. de, Claassen, W.J., Grondman, I., Janssen, N.A.F., Netea, M.G., Veerdonk, F.L. van de, Hoeven, J.G. van der, Hemelaar, P., Beunders, R., Frenzel, T., Schouten, J.A., Gerretsen, J.J.F., Heesakkers, H.G.P., Joosten, L.A.B., Mast, Q. de, Jaeger, M., Kouijzer, I.J.E., Dijkstra, H.I., Lemmers, H.L.M., Crevel, R. van, Maat, J.S. van de, Moorlag, S.J.C.F.M., Taks, E.J.M., Debisarun, A., Wertheim, H.F.L., Hopman, J., Rahamat-Langendoen, J.C., Bleeker-Rovers, C.P., Koenen, H.J., Fasse, E., Rijssen, E. van, Cranenbroek, B. van, Smeets, R.L., Joosten, I., Kox, M., and Pickkers, P.

Abstract

Item does not contain fulltext, BACKGROUND/OBJECTIVES: Obesity appears to be an independent risk factor for ICU admission and a severe disease course in COVID-19 patients. An aberrant inflammatory response and impaired respiratory function have been suggested as underlying mechanisms. We investigated whether obesity is associated with differences in inflammatory, respiratory, and clinical outcome parameters in critically ill COVID-19 patients. SUBJECTS/METHODS: Sixty-seven COVID-19 ICU patients were divided into obese (BMI ≥ 30 kg/m(2), n = 18, 72% class I obesity, 28% class II obesity) and non-obese (BMI < 30 kg/m(2), n = 49) groups. Concentrations of circulating interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interferon gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, and IL-1 receptor antagonist (RA) were determined from ICU admission until 10 days afterward, and routine laboratory and clinical parameters were collected. RESULTS: BMI was 32.6 [31.2-34.5] and 26.0 [24.4-27.7] kg/m(2) in the obese and non-obese group, respectively. Apart from temperature, which was significantly lower in obese patients (38.1 [36.9-38.9] vs. 38.7 [38.0 -39.5] °C, p = 0.02), there were no between-group differences on ICU admission. Plasma cytokine concentrations declined over time (p < 0.05 for all), but no differences between obese and non-obese patients were observed. Also, BMI did not correlate with the cytokine response (IL-6 r = 0.09, p = 0.61, TNF-α r = 0.03, p = 0.99, IP-10 r = 0.28, p = 0.11). The kinetics of clinical inflammatory parameters and respiratory mechanics were also similar in both groups. Finally, no differences in time on ventilator, ICU length of stay or 40-day mortality between obese and non-obese patients were apparent. CONCLUSIONS: In COVID-19 patients requiring mechanical ventilation in the ICU, a higher BMI is not related to a different immunological response, unfavorable respiratory mechanics, or impaired outcome.

Published
2021

6. Safety and Efficacy of Human Chorionic Gonadotropin Hormone-Derivative EA-230 in Cardiac Surgery Patients: A Randomized Double-Blind Placebo-Controlled Study

Author

Groenendael, R. van, Beunders, R., Hemelaar, P., Hofland, J., Morshuis, W.J., Hoeven, J.G. van der, Gerretsen, J.J.F., Wensvoort, G., Kooistra, E.J., Claassen, W.J., Waanders, Denise, Lamberts, M.G.A., Buijsse, L.S.E., Kox, M., Eijk, L.T.G.J. van, Pickkers, P., Groenendael, R. van, Beunders, R., Hemelaar, P., Hofland, J., Morshuis, W.J., Hoeven, J.G. van der, Gerretsen, J.J.F., Wensvoort, G., Kooistra, E.J., Claassen, W.J., Waanders, Denise, Lamberts, M.G.A., Buijsse, L.S.E., Kox, M., Eijk, L.T.G.J. van, and Pickkers, P.

Abstract

Contains fulltext : 232791.pdf (Publisher’s version ) (Open Access), OBJECTIVES: To determine the safety and efficacy of human chorionic gonadotropin hormone-derivative EA-230 in cardiac surgery patients. Cardiac surgery induces systemic inflammation and may impair renal function, affecting patient outcome. EA-230 exerted immunomodulatory and renoprotective effects in preclinical models and was safe and showed efficacy in phase I and II human studies. DESIGN: Double-blinded, placebo-controlled, randomized study. SETTING: Collaboration of the Cardiothoracic Surgery, Anesthesiology, and the Intensive Care departments of a tertiary hospital in the Netherlands. PATIENTS: One hundred eighty patients undergoing an on-pump coronary artery bypass procedure with or without concomitant valve surgery. INTERVENTIONS: Ninety mg/kg/hr EA-230 or placebo administered during surgery. MEASUREMENTS AND MAIN RESULTS: During the study, no safety concerns emerged. EA-230 did not modulate interleukin-6 plasma concentrations (area under the curve 2,730 pg/mL x hr [1,968-3,760] vs 2,680 pg/mL x hr [2,090-3,570] for EA-230 and placebo group, respectively; p = 0.80). Glomerular filtration rate increased following surgery (mean +/- SEM increase in the EA-230 vs placebo groups: glomerular filtration rateiohexol measured using iohexol plasma clearance: 19 +/- 2 vs 16 +/- 2 mL/min/1.73 m2; p = 0.13 and estimated glomerular filtration rate with the Modification of Diet in Renal Disease equation using creatinine: 6 +/- 1 vs 2 +/- 1 mL/min/1.73 m2; p = 0.01). The "injury" stage of the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease criteria for acute kidney injury was 7% in the EA-230 group versus 18% in the placebo group (p = 0.07). In addition, EA-230-treated patients had a less positive fluid balance compared with placebo-treated patients (217 +/- 108 vs 605 +/- 103 mL; p = 0.01), while the use of vasoactive agents was similar in both groups (p = 0.39). Finally, hospital length of stay was shorter in EA-230 treated patients (8 d [7-11]

Published
2021

8. Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients

Author

Aschenbrenner, Anna C., Mouktaroudi, Maria, Kraemer, Benjamin, Oestreich, Marie, Antonakos, Nikolaos, Nuesch-Germano, Melanie, Bruse, N., Gerretsen, J.J.F., Pickkers, P., Veerdonk, F.L. van de, Netea, M.G., Kox, M., Giamarellos-Bourboulis, Evangelos J., Ulas, Thomas, Aschenbrenner, Anna C., Mouktaroudi, Maria, Kraemer, Benjamin, Oestreich, Marie, Antonakos, Nikolaos, Nuesch-Germano, Melanie, Bruse, N., Gerretsen, J.J.F., Pickkers, P., Veerdonk, F.L. van de, Netea, M.G., Kox, M., Giamarellos-Bourboulis, Evangelos J., and Ulas, Thomas

Abstract

Contains fulltext : 230556.pdf (publisher's version ) (Open Access)

Published
2021

9. Case-control study on the interplay between immunoparalysis and delirium after cardiac surgery

Author

Cheheili Sobbi, S., Peters van Ton, A.M., Wesselink, E., Looije, Marjolein F., Gerretsen, J.J.F., Morshuis, W.J., Pickkers, P., Boogaard, M. van den, Cheheili Sobbi, S., Peters van Ton, A.M., Wesselink, E., Looije, Marjolein F., Gerretsen, J.J.F., Morshuis, W.J., Pickkers, P., and Boogaard, M. van den

Abstract

Contains fulltext : 236794.pdf (Publisher’s version ) (Open Access)

Published
2021

10. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes

Author

Nooijer, A.H. de, Grondman, I., Janssen, N.A.F., Netea, M.G., Willems, Loek, Veerdonk, F.L. van de, Giamarellos-Bourboulis, E.J., Jaeger, M., Dijkstra, H.I., Lemmers, H.L.M., Emst, L. van, Schraa, K., Jacobs, C.W.M., Hijmans, A.G., Jansen, T.J.G., Weren, F.B.M., Fransman, L.H.G., Gerretsen, J.J.F., Maat, J.S. van de, Nijman, G., Moorlag, S.J.C.F.M., Taks, E.J.M., Debisarun, A., Kouijzer, I.J.E., Wertheim, H.F.L., Hopman, J., Rahamat-Langendoen, J.C., Bleeker-Rovers, C.P., Oever, J. ten, Crevel, R. van, Hoogerwerf, J.J., Mast, Q. de, Hoeven, H. van der, Pickkers, P., Kox, M., Frenzel, T., Schouten, J.A., Hemelaar, P., Beunders, R., Velde, Sjef van der, Kooistra, E.J., Waalders, N.J.B., Klop-Riehl, M., Toonen, E.J.M., Joosten, L.A.B., Nooijer, A.H. de, Grondman, I., Janssen, N.A.F., Netea, M.G., Willems, Loek, Veerdonk, F.L. van de, Giamarellos-Bourboulis, E.J., Jaeger, M., Dijkstra, H.I., Lemmers, H.L.M., Emst, L. van, Schraa, K., Jacobs, C.W.M., Hijmans, A.G., Jansen, T.J.G., Weren, F.B.M., Fransman, L.H.G., Gerretsen, J.J.F., Maat, J.S. van de, Nijman, G., Moorlag, S.J.C.F.M., Taks, E.J.M., Debisarun, A., Kouijzer, I.J.E., Wertheim, H.F.L., Hopman, J., Rahamat-Langendoen, J.C., Bleeker-Rovers, C.P., Oever, J. ten, Crevel, R. van, Hoogerwerf, J.J., Mast, Q. de, Hoeven, H. van der, Pickkers, P., Kox, M., Frenzel, T., Schouten, J.A., Hemelaar, P., Beunders, R., Velde, Sjef van der, Kooistra, E.J., Waalders, N.J.B., Klop-Riehl, M., Toonen, E.J.M., and Joosten, L.A.B.

Abstract

Contains fulltext : 232398.pdf (Publisher’s version ) (Open Access), BACKGROUND: Excessive activation of immune responses in coronavirus disease 2019 (COVID-19) is considered to be related to disease severity, complications, and mortality rate. The complement system is an important component of innate immunity and can stimulate inflammation, but its role in COVID-19 is unknown. METHODS: A prospective, longitudinal, single center study was performed in hospitalized patients with COVID-19. Plasma concentrations of complement factors C3a, C3c, and terminal complement complex (TCC) were assessed at baseline and during hospital admission. In parallel, routine laboratory and clinical parameters were collected from medical files and analyzed. RESULTS: Complement factors C3a, C3c, and TCC were significantly increased in plasma of patients with COVID-19 compared with healthy controls (P < .05). These complement factors were especially elevated in intensive care unit patients during the entire disease course (P < .005 for C3a and TCC). More intense complement activation was observed in patients who died and in those with thromboembolic events. CONCLUSIONS: Patients with COVID-19 demonstrate activation of the complement system, which is related to disease severity. This pathway may be involved in the dysregulated proinflammatory response associated with increased mortality rate and thromboembolic complications. Components of the complement system might have potential as prognostic markers for disease severity and as therapeutic targets in COVID-19.

Published
2021

11. Phenylephrine impairs host defence mechanisms to infection: a combined laboratory study in mice and translational human study

Author

Stolk, R.F., Naumann, F.V., Pasch, E. van der, Schouwstra, J., Bressers, S., Herwaarden, A.E. van, Gerretsen, J.J.F., Ruth, M.M., Hoeven, H. van der, Pickkers, P., Kox, M., Stolk, R.F., Naumann, F.V., Pasch, E. van der, Schouwstra, J., Bressers, S., Herwaarden, A.E. van, Gerretsen, J.J.F., Ruth, M.M., Hoeven, H. van der, Pickkers, P., and Kox, M.

Abstract

Contains fulltext : 231953.pdf (Publisher’s version ) (Open Access)

Published
2021

13. Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times?

Author

Berkel, M. van, Kox, M., Frenzel, T., Bruse, N., Kooistra, E.J., Touw, H.R.W., Hemelaar, P., Beunders, R., Hoeven, J.G. van der, Gerretsen, J.J.F., Heesakkers, H.G.P., Netea, M.G., Joosten, L.A.B., Janssen, N.A.F., Grondman, I., Nooijer, A.H. de, Mast, Q. de, Jaeger, M., Kouijzer, I.J.E., Lemmers, H.L.M., Crevel, R. van, Maat, J.S. van de, Moorlag, S.J.C.F.M., Taks, E.J.M., Debisarun, A., Wertheim, H.F.L., Hopman, J., Rahamat-Langendoen, J.C., Bleeker-Rovers, C.P., Fasse, E., Rijssen, E. van, Cranenbroek, B. van, Smeets, R.L., Joosten, I., Pickkers, P., and Schouten, J.A.

Subjects
Male, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], MEDLINE, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Antimicrobial stewardship, Critical Care and Intensive Care Medicine, Procalcitonin, Pandemic, Research Letter, medicine, Humans, Pandemics, Aged, Viral Epidemiology, business.industry, Other Research Radboud Institute for Health Sciences [Radboudumc 0], lcsh:Medical emergencies. Critical care. Intensive care. First aid, COVID-19, Metabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6], lcsh:RC86-88.9, Middle Aged, medicine.disease, Virology, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Anti-Bacterial Agents, COVID-19 Drug Treatment, Pneumonia, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], C-Reactive Protein, Female, Coronavirus Infections, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Biomarkers
Abstract

Contains fulltext : 229373.pdf (Publisher’s version ) (Open Access)

Published
2020
Full Text
View/download PDF

14. Norepinephrine Dysregulates the Immune Response and Compromises Host Defense during Sepsis

Author

Stolk, R.F., Pasch, E. van der, Naumann, F.V., Schouwstra, J., Bressers, S., Herwaarden, A.E. van, Gerretsen, J.J.F., Schambergen, R., Ruth, M.M., Hoeven, J.G. van der, Leeuwen, H. van, Pickkers, P., Kox, M., Stolk, R.F., Pasch, E. van der, Naumann, F.V., Schouwstra, J., Bressers, S., Herwaarden, A.E. van, Gerretsen, J.J.F., Schambergen, R., Ruth, M.M., Hoeven, J.G. van der, Leeuwen, H. van, Pickkers, P., and Kox, M.

Abstract

Contains fulltext : 225483.pdf (Publisher’s version ) (Closed access), Rationale: Sepsis is characterized by a dysregulated immune response to infection. Norepinephrine, the cornerstone vasopressor used in septic shock, may contribute to immune dysregulation and impact host defense.Objectives: To investigate effects of norepinephrine and the alternative vasopressor vasopressin on the immune response and host defense.Methods: Leukocytes from six to nine donors were stimulated in the presence or absence of norepinephrine and vasopressin. A total of 190 C57BL/6J mice received a continuous infusion of norepinephrine or vasopressin via microosmotic pumps and were challenged with LPS or underwent cecal ligation and puncture. Thirty healthy volunteers were randomized to a 5-hour infusion of norepinephrine, vasopressin, or saline and intravenously challenged with LPS. The relationship between the norepinephrine infusion rate and the use of β-blockers and plasma cytokines was assessed in 195 patients with septic shock.Measurements and Main Results: Norepinephrine attenuated the production of proinflammatory mediators and reactive oxygen species and augmented antiinflammatory IL-10 production both in vitro and in LPS-challenged mice. Norepinephrine infusion during cecal ligation and puncture resulted in increased bacterial dissemination to the spleen, liver, and blood. In LPS-challenged volunteers, norepinephrine enhanced plasma IL-10 concentrations and attenuated the release of the proinflammatory cytokine IFN-γ-induced protein 10. Vasopressin exerted no immunomodulatory effects across these experimental setups. In patients, higher norepinephrine infusion rates were correlated with a more antiinflammatory cytokine balance, whereas β-blocker use was associated with a more proinflammatory cytokine balance.Conclusions: Norepinephrine dysregulates the immune response in mice and humans and compromises host defense. Therefore, it may significantly contribute to sepsis-induced immunoparalysis, whereas vasopressin does not have untoward immunologic ef

Published
2020

15. COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients

Author

Kox, M., Frenzel, T., Schouten, J.A., Veerdonk, F.L. van de, Hemelaar, P., Beunders, R., Hoeven, J.G. van der, Gerretsen, J.J.F., Netea, M.G., Joosten, L.A.B., Janssen, N.A.F., Grondman, I., Nooijer, A.H. de, Mast, Q. de, Jaeger, M., Kouijzer, I.J.E., Lemmers, H.L.M., Crevel, R. van, Maat, J.S. van de, Moorlag, S.J.C.F.M., Taks, E.J.M., Debisarun, A., Wertheim, H.F.L., Hopman, J., Rahamat-Langendoen, J.C., Bleeker-Rovers, C.P., Fasse, E., Rijssen, E. van, Cranenbroek, B. van, Smeets, R.L., Joosten, I., Koenen, H.J., Pickkers, P., Kox, M., Frenzel, T., Schouten, J.A., Veerdonk, F.L. van de, Hemelaar, P., Beunders, R., Hoeven, J.G. van der, Gerretsen, J.J.F., Netea, M.G., Joosten, L.A.B., Janssen, N.A.F., Grondman, I., Nooijer, A.H. de, Mast, Q. de, Jaeger, M., Kouijzer, I.J.E., Lemmers, H.L.M., Crevel, R. van, Maat, J.S. van de, Moorlag, S.J.C.F.M., Taks, E.J.M., Debisarun, A., Wertheim, H.F.L., Hopman, J., Rahamat-Langendoen, J.C., Bleeker-Rovers, C.P., Fasse, E., Rijssen, E. van, Cranenbroek, B. van, Smeets, R.L., Joosten, I., Koenen, H.J., and Pickkers, P.

Abstract

Contains fulltext : 220045.pdf (publisher's version ) (Open Access)

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results